Background: In patients with advanced colorectal cancer, KRAS mutation status predicts response to treatment with monoclonal antibody targeting the epithelial growth factor receptor (EGFR). Recent reports have provided evidence that KRAS mutation status has prognostic value in patients with resectable colorectal liver metastases (CLM) irrespective of treatment with chemotherapy or anti-EGFR therapy. A meta-analysis was undertaken to clarify the impact of KRAS mutation on outcomes in patients with resectable CLM.
Introduction
In the evaluation of patients for resection of colorectal liver metastases (CLM), extent of disease is the primary consideration. Resection of all viable disease with acceptable postoperative morbidity is crucial to maximize the survival benefit and achieve cure. Improvements in surgical and non-surgical techniques have increased the proportion of patients eligible for curative resection of CLM 1 . However, for a number of patients rapid recurrence or postoperative complications offset the benefit associated with surgery.
In the 1990s, several groups 2 -4 published scoring systems to predict recurrence after resection of CLM on the basis of clinical parameters such as sex, age, tumour location, size and number, disease-free interval and disease stage. However, risk factors determined before the era of modern chemotherapy have been shown 5 -7 to perform less well in recent series of patients with CLM, in whom liver resection was performed in combination with modern chemotherapy. Compared with clinical parameters that serve as surrogate markers for tumour biology, direct indicators of tumour biology may explain the diverse outcomes after resection of CLM and provide useful information to guide treatment of patients with CLM.
Currently, medical oncologists are using the mutation status of the Kirsten rat sarcoma viral oncogene homologue (KRAS) gene to select patients with advanced-stage colorectal cancer with wild-type KRAS for treatment with monoclonal antibodies that target the epithelial growth factor receptor (EGFR); the antibodies used are panitumumab and cetuximab 8 -11 . Recently, mutations in the KRAS gene have received much attention as the most promising mutations for prognostication in patients undergoing resection of CLM 12 -14 , indicating that knowledge of KRAS mutation status may also be valuable for evaluation of patients for possible resection of CLM. To clarify the value of KRAS mutation status in predicting outcome after resection of CLM, a systematic literature review and meta-analysis was performed of studies reporting overall (OS) and recurrence-free (RFS) survival stratified by KRAS mutation status (irrespective of chemotherapy and anti-EGFR treatment) in patients undergoing CLM resection.
Methods

Data sources and search strategy
A systematic literature review was performed in April 2014 using the US National Library of Medicine PubMed database, Embase and the Cochrane Library. A detailed search string was constructed to return full-text articles that reported studies with patients who had resection of CLM and that provided information regarding outcome and KRAS mutation status: 'colorectal AND cancer AND (liver OR hepatic) AND (metastasis OR metastases) AND (resection OR surgery OR hepatectomy) AND (mutation OR mutations) AND (KRAS OR K-RAS OR NRAS OR N -RAS OR RAS)'. The review adhered to the guidelines outlined in the PRISMA statement 15 .
Selection criteria
To be included in the review, an article had to: report on a study that included and reported patients who underwent resection of CLM; include results of genetic testing for KRAS mutations; and include outcomes for survival or recurrence assessed against the mutations. Publication date was not an inclusion or exclusion criterion. Duplicate articles were removed and the title of the remaining articles was reviewed; if the title did not reveal a reason for exclusion, the abstract was used to determine whether the article or study met any of the following exclusion criteria: language other than English; primary cancer other than colorectal cancer; article type other than report of original research (review, editorial, letter, comment, case report, or abstract); only the primary tumour treated with surgery; oncological but not surgical outcome reported; survival or recurrence not a primary or secondary outcome; basic science report; or study in cell lines or animals. The reference lists of the remaining articles were assessed for missed studies meeting the inclusion criteria. A qualitative systematic literature review and critical evaluation of the evidence were performed. Articles reporting KRAS mutation effect estimates from multivariable analyses for OS and articles reporting RFS after resection of CLM were pooled in separate meta-analyses.
Records identified through database search n = 355
PubMed n = 166 Embase n = 166 Cochrane Library n = 23
Additional records identifed through reference lists and meeting inclusion criteria n = 1 Records meeting inclusion criteria n = 14 Reporting OS n = 11 Reporting RFS n = 7
Excluded (abstracts) n = 4
Records for systematic selection n = 17
Unique records in English, CRC n = 223
Excluded n = 206 Metastases not resected n = 50 No surgical outcomes n = 90 Endpoint not survival n = 51 Basic science non-human n = 15
Excluded n = 132 Duplicates n = 28 Non-English n = 16 Non-CRC n = 23 Reviews/editorial/letters n = 61 Case reports n = 4 The search string was built to identify studies of patients undergoing resection of colorectal liver metastases (CLM) in whom survival was assessed according to KRAS mutation status. CRC, colorectal cancer; OS, overall survival; RFS, recurrence-free survival
Data extraction and outcome measures
The following data were extracted from the included articles: first author, study origin, year of publication, study period, sample size, metastatic site, rate of KRAS mutations, KRAS codons included in the mutational analysis, use of preoperative chemotherapy (regimen and number of patients), use of adjuvant chemotherapy (regimen and number of patients), summary of findings regarding survival, and multivariable effect estimates for OS and RFS (hazard ratio (HR), 95 per cent c.i., P value). The individual studies were graded into low or high risk of bias based on the Grading of Recommendations, Assessment Development and Evaluation (GRADE) Working Group criteria: quality of evidence, uncertainty about the balance between desirable and undesirable effects, uncertainty of variability in values and preference, and uncertainty about whether the intervention represents a wise use of resources (www.gradeworkinggroup.org). The following study characteristics were assessed in light of the GRADE criteria and a concern regarding individual study bias: sample size, heterogeneity of selection to chemotherapy and resection, unresectability, study interval, lung and not liver resections, KRAS codons tested, other included genes, heterogeneity regarding variables included in multivariable analysis, and consistency of findings.
Statistical analysis
The primary outcome of the study was OS after resection of CLM; the secondary outcome was RFS after resection of CLM. Meta-analyses were performed using HRs with 95 per cent c.i.; the chosen effect measure was dichotomous data, which were available in 11 articles (8 of which reported OS and 7 RFS). The effect measures were converted into logarithmic values and a random-effects model with inverse-variance method was used to calculate weight and overall results of the meta-analyses. Interstudy statistical heterogeneity was assessed with I 2 statistics, and moderate to high degree was assumed when the value was more than 30 per cent. Data were presented in Forest plots in which a HR of less than 1 represents better outcome and a HR of more than 1 represents worse outcome in patients harbouring a KRAS mutation. Funnel plot analyses were performed to evaluate the presence of publication bias. Where some summary statistics for OS were reported for patients with KRAS and wild-type mutations, but the HR and 95 per cent c.i. were not made available in the article, these studies were assessed individually and not included in the main meta-analysis. Stata/SE™ version 11⋅0 (StataCorp LP, College Station, Texas, USA) was used for the meta-analyses.
Results
Literature search result
The initial search returned 355 records (Fig. 1) ; after exclusions, 223 articles remained for assessment of eligibility. After application of the other exclusion criteria and review of reference lists for missed articles, 14 unique articles remained 12 -14,16-26 ( Tables 1 and 2 ). These 14 articles reported on 1809 patients, 1725 of whom had resection of CLM. The KRAS mutation rate among all patients was 30⋅6 per cent.
Assessment of the study characteristics based on the GRADE criteria found that two studies 16, 17 (n = 84) included patients with unresectable CLM, one study 18 (n = 17) included patients with lung metastasis, one study 19 tested KRAS codons 12 only, and one study 20 (n = 6) included BRAF mutations in the survival analysis. The risk of individual study bias was assessed as low 12 -14,16,18,20-25 and high 17, 19, 26 in the included articles.
KRAS mutation and overall survival
Eight 12 -14,16,19,20,23,24 of the 14 studies reported OS after resection of CLM stratified by KRAS mutation status and were pooled in a meta-analysis (Fig. 2) . Three 17, 18, 26 of the 14 studies did not perform multivariable analyses for OS, two 21, 25 reported RFS only, and one 22 reported results from the same patient cohort as another study 20 that was included in the meta-analysis. The study by *Chemotherapy used in study, but only in patients with unresectable disease. Chemotherapy used at some point in †29, ‡161, §14 and ¶142 patients, but adjuvant for primary versus preoperative/adjuvant for liver frequencies not available (n.a.). #Liver KRAS mutation rate. **One patient received cetuximab before resection of colorectal liver metastases (CLM), and three patients received cetuximab/panitumumab after resection of CLM. † †Chemotherapy was given only to patients with initially unresectable CLM. ‡ ‡Includes NRAS mutations. 5-FU, 5-fluorouracil-based chemotherapy; OS, overall survival; OXA, oxaliplatin; IRI, irinotecan; RFS, recurrence-free survival; BEV, bevacizumab; HAI, hepatic arterial infusion.
Huang and colleagues 20 was included in the meta-analysis because these authors included KRAS mutations in the multivariable analysis. The eight studies included in the meta-analysis represented 1181 patients who underwent resection of CLM; in these patients the KRAS mutation rate was 27⋅6 per cent. The results from these eight studies were generally consistent and KRAS mutation was negatively associated with OS (HR 2⋅24, 95 per cent c.i. 1⋅76 to 2⋅85). The funnel plot did not suggest notable publication bias (data not shown). Three early studies reported overall survival in 19 26 , 13 17 and 110 18 patients who underwent resection of CLM without providing HR and 95 per cent c.i. for KRAS mutations from multivariable analysis. These studies were assessed individually; no significant association between KRAS mutation and OS was found.
KRAS mutation and recurrence-free survival
Seven 12 -14,18,21,24,25 of the 14 studies included in the systematic literature review reported RFS. Multivariable Cox regression analysis was performed for all seven studies, and the HR data were pooled in a separate meta-analysis (Fig. 3) . The seven studies reported a total of 906 patients undergoing resection of CLM; in these patients the KRAS Petrowsky et al. 19 Nash et al. 16 Stremitzer et al. 13 Huang et al. 20 Umeda et al. 23 Vauthey et al. 14 Karagkounis et al. 12 Kemeny et al. 24 Overall (I 2 = 0·0%, P = 0·965) Cejas et al. 18 Isella et al. 21 Stremitzer et al. 13 Shoji et al. 25 Vauthey et al. 14 Karagkounis et al. 12 Kemeny et al. 24 Overall (I 2 = 0·0%, P = 0·997) Fig. 3 Forest plot of association between KRAS mutation status and recurrence-free survival (RFS) after resection of colorectal liver metastases in seven studies. A random-effects model with inverse-variance method was used for meta-analysis. Hazard ratios are shown with 95 per cent c.i. mutation rate was 28⋅0 per cent. The results from these seven studies were consistent and KRAS mutation was negatively associated with RFS (HR 1⋅89, 95 per cent c.i. 1⋅54 to 2⋅32).
Discussion
In the meta-analyses reported here, KRAS mutations predicted inferior OS and inferior RFS among patients who had resection of CLM. The effect of KRAS mutations on survival cannot be attributed to the perioperative use of targeted agents, as perioperative anti-EGFR treatment was used in only four of 100 patients in just one study 23 . Furthermore, the superior RFS in patients with wild-type KRAS indicates that the impact of KRAS mutation in the present study was not due to treatment of recurrence with anti-EGFR.
KRAS mutations have been associated with migration and invasion through disruption of the actin cytoskeleton and regulation of integrin expression, among other mechanisms 27 -29 . These behaviors are mediated via a wider class of effectors beyond the mitogenactivated protein kinase pathway, including Rho guanosine-5 ′ -triphosphatases and Rap1 30, 31 . As a result, the prognostic importance of activating KRAS mutations extends beyond their ability to predict sensitivity to anti-EGFR monoclonal antibodies, and KRAS mutations may reflect a more migratory and invasive tumour biology resulting in a propensity for early and frequent recurrences after resection of metastatic disease.
The pooled KRAS mutation rate in the present study, 30⋅6 per cent, was lower than the 35-45 per cent rates that have been reported in most studies of patients with metastatic colorectal cancer 13,14,19,32 -34 . The high concordance of KRAS mutation status between primary colorectal tumours and metastatic sites (more than 90 per cent) indicates that mutations are acquired early in tumorigenesis, before metastatic spread 35, 36 . As such, the lower rate of KRAS mutations in the present study is unlikely to be due to differences in the tissue source for the KRAS testing 18,37 -39 . Instead, patients who are deemed candidates for surgery are more likely than those not deemed candidates for surgery to have oligometastatic disease, reflecting potential differences in metastatic propensity. The lower KRAS mutation rate in the present study is in agreement with recent findings demonstrating significantly higher KRAS mutation rates in patients with extrahepatic metastasis from colorectal cancer than in patients with CLM, and unresectable extrahepatic disease is in most patients considered a contraindication for resection of CLM 18, 37, 40 .
Although the survival impact of KRAS mutations has been demonstrated across multiple studies utilizing the most common codons in KRAS (12 and 13) 32 , recent data on resistance to anti-EGFR monoclonal antibodies have suggested that the current standard-of-care panel should be expanded to include codons in exons 3 (codon 61) and exon 4 (codon 146) of KRAS 41 . These KRAS alleles were included in several studies 13, 14, 21 in the present metaanalysis. The rarity of mutations in these additional alleles precludes testing of their individual prognostic impact, but their mutual exclusivity in patients 37 and ability to transform cells in vitro suggest that their oncogenic function is preserved and that these alleles should therefore be included in testing panels for assessment of RAS mutation status 9, 42, 43 . A recent analysis 9 indicated that NRAS mutations should also be considered in the determination of RAS mutation status. In one study 14 included in the present meta-analyses, the investigators analysed all RAS mutations (NRAS and extended KRAS to include codon 61 and 146); the addition of NRAS increased the yield of RAS mutations by 20 per cent and likely strengthened the impact of mutations on prognosis.
The main challenge in patients with CLM is to identify those who can derive a survival benefit from resection. Historically, predictors of survival were based on morphological characteristics of the primary tumour and metastases (including primary tumour location and TNM stage; number and size of liver metastases), carcinoembryonic antigen level, and the disease-free interval between detection of the primary tumour and metastasis. Various scores with combinations of these factors have been proposed to predict prognosis after resection of CLM 2 -4,44-48 . However, in recent years, large single-institution studies have questioned the validity and clinical usefulness of risk scores 5 -7 . Zakaria and colleagues 7 found that risk scoring systems had limited clinical value, and Kattan and co-workers 49 created a nomogram with better discriminatory ability to improve scoring in resectable CLM. The studies used in the present meta-analyses assessed many of these factors in multivariable analysis, and KRAS mutations consistently indicated an independent twofold increase in the risk of death (8 studies) or recurrence (7 studies). In recent years, investigators have proposed pathological and radiological responses to chemotherapy as alternative outcome endpoints for predicting survival after resection of CLM 50 -52 . However, pathological response can be assessed only after surgery, and the survival association with radiological response was found to be present mostly in patients receiving preoperative antivascular endothelial growth factor therapy 50 -53 . In this context, KRAS mutation stands out as a new predictor of prognosis in patients with resectable CLM. It has many advantages over tumour characteristics and response to chemotherapy, as KRAS mutation is an early event in carcinogenesis that appears to be unaffected by chemotherapy 54 .
This study has several limitations. First, there may be heterogeneity between the studies regarding the definition of resectability (between centres and surgeons), the use of chemotherapy, and the factors analysed in multivariable analysis. Despite this, the effect of KRAS on survival was consistent in almost all of the included studies, and no studies were identified reporting a favourable outcome in patients harbouring KRAS mutations. Such findings would have been published by now, and the funnel plot analyses of the included studies did not suggest publication bias. Second, some patients with wild-type KRAS may have received anti-EGFR treatment at the time of recurrence after liver resection, which could explain the OS benefit in these patients. However, this concern would have applied only to OS and not to RFS, and the majority of the study intervals predated the approval of anti-EGFR treatment for colorectal cancer. Third, a recent editorial 55 raised the possibility that KRAS mutation may be a 'byproduct of patient selection' that would explain the association with inferior survival. However, up to now, surgeons have determined patient resectability based on tumour and biological characteristics irrespective of KRAS mutation status. Furthermore, KRAS mutation testing may have been utilized in the patients with the most extensive disease, but this selection could not explain the OS and RFS differences between the included mutants and wild-types.
This meta-analysis indicates that KRAS mutation status is a prognostic factor in patients undergoing resection of CLM irrespective of chemotherapy regimen and should be considered in the evaluation of patients undergoing liver resection for CLM. In practice, the use of KRAS mutation status alone cannot be recommended as grounds for excluding patients from surgery, but the finding of wild-type KRAS may encourage the use of more aggressive treatment in patients with borderline resectable disease. KRAS mutation status is clearly useful, together with other clinicopathological predictors, both in the preoperative assessment of patients with CLM and at follow-up to assess the risk of recurrence and death.
